Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 10 - 14 save search
MemorialCare Earns National Recognition for Efforts to Improve Cardiovascular, Diabetes and Stroke Treatment
Published: 2021-10-14 (Crawled : 21:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: 0.19%
H: 0.0%
C: 0.0%
diabetes treatment stroke cardiovascular cardio
TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Published: 2021-10-14 (Crawled : 15:00) - globenewswire.com
TGTX | News | $14.0 1.3% 1.29% 3.5M
|
Health Technology
|
| O: 0.82%
H: 3.21%
C: 2.66%
multiple sclerosis treatment europe sclerosis research
electroCore Announces Regulatory Approval in Canada to Treat Adolescent MigraineHealth Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescents
Published: 2021-10-14 (Crawled : 14:15) - biospace.com/
ECOR | $5.72 2.41% 2.36% 5.7K
|
Health Technology
|
| O: 1.96%
H: 0.96%
C: -3.85%
treatment migraine approval
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
IBRX | $4.92 -6.11% -6.5% 3.5M
|
Manufacturing
|
| O: 0.99%
H: 8.76%
C: 4.24%
treatment phase 2 cancer pancreatic pancreas enroll
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock Tuesday, October 19th @ 8:00 am Eastern Time
Published: 2021-10-14 (Crawled : 12:15) - biospace.com/
WINT | News | $0.3399 -15.3% -18.06% 1.8M
|
Health Technology
|
| O: 1.32%
H: 1.74%
C: -0.87%
treatment heart cardio
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Published: 2021-10-14 (Crawled : 12:15) - biospace.com/
BCLI | $0.503 -6.99% -7.51% 1.1M
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: -3.38%
multiple sclerosis treatment phase 2 europe sclerosis research trial
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration
Published: 2021-10-14 (Crawled : 12:00) - globenewswire.com
VRDN | $15.17 0.6% 0.59% 580K
|
Health Care and Social Assistan...
|
| O: 0.36%
H: 6.46%
C: -0.48%
new drug disease food treatment eye eye disease antibody drug
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Published: 2021-10-14 (Crawled : 12:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 1.42%
H: 3.26%
C: 1.86%
chinese treatment cancer biotech iot breast cancer trial
FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.2%
H: 0.08%
C: -0.43%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 1.07%
H: 2.19%
C: 0.47%
covid treatment fda casirivimab fda acceptance
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
KRYS | $164.04 -3.3% -3.41% 280K
|
Health Technology
|
| O: 1.89%
H: 1.29%
C: -0.63%
presentation treatment pre-clinical biotech iot preclinical
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock
Published: 2021-10-14 (Crawled : 12:00) - globenewswire.com
WINT | News | $0.3399 -15.3% -18.06% 1.8M
|
Health Technology
|
| O: 1.32%
H: 1.74%
C: -0.87%
treatment heart cardio
Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure
Published: 2021-10-14 (Crawled : 11:00) - prnewswire.com
NRXP 1 d | $3.025 -27.63% -38.18% 760K
|
Manufacturing
|
| O: 27.44%
H: 12.14%
C: -1.0%
covid disease treatment infectious disease positive respiratory trial aviptadil
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.